Table 5.
Study groups |
||
---|---|---|
QUICKI ≥ 0.357 n = 186 |
QUICKI < 0.357 n = 258 |
|
Metabolic syndrome (%) | 15.6 | 62.4* |
Age (years) | 39.2 ± 10.9 | 37.8 ± 12.1 |
BMI (kg/m2) | 25.8 ± 3.8 | 30.3 ± 5.1** |
WC (cm) | 86.7 ± 10.0 | 98.3 ± 12.1*** |
%BF | 29.9 ± 8.4 | 36.6 ± 6.7** |
FH-T2D (%) | 55.9 | 62.8 |
SBP (mm Hg) | 103.8 ± 12.9 | 110.8 ± 14.4*** |
DBP (mm Hg) | 69.4 ± 8.7 | 74.8 ± 9.5** |
Gluc0h (mg/dL) | 88.1 ± 8.1 | 100.8 ± 22.0** |
Ins0h (μU/mL) | 4.8 ± 1.4 | 11.9 ± 4.9** |
HOMA-IR | 1.1 ± 0.3 | 3.0 ± 1.6** |
HOMA-β | 76.5 ± 40.7 | 126.9 ± 61.3** |
HDL-C (mg/dL) | 47.6 ± 12.9 | 39.6 ± 9.6** |
TAG (mg/dL) | 109.7 ± 50.8 | 172.3 ± 86.5** |
TAG/HDL-C | 2.5 ± 1.5 | 4.8 ± 3.0** |
CVI | 4.2 ± 1.3 | 5.1 ± 1.3*** |
Notes: Results are expressed as mean ± standard deviation.
P ≤ 0.05, Fisher’s exact test for two proportions;
P ≤ 0.05, Mann–Whitney U test;
P ≤ 0.05, Kruskal–Wallis one-way analysis of variance.
Abbreviations: BMI, body mass index; WC, waist circumference; %BF, % body fat; SBP, systolic blood pressure; DBP, diastolic blood pressure; Glc0h, fasting glucose; Ins0h, fasting insulin; HDL-C, cholesterol combined with high-density lipoprotein; TAG, triacylglycerides; HOMA-IR, homeostatic model assessment of insulin resistance; HOMA-β, homeostatic model assessment of β-cell function; QUICKI, index to check the quantitative insulin sensitivity; FH-T2D, family history of type 2 diabetes mellitus; CVI, Castelli Cardiovascular Index.